CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
Summary
CD22 is a potential tumor surface antigen capable of being targeted by CAR-NK cells in ESCC. And potential therapeutics for ESCC may be developed based on immune cells expressing anti-CD22 CAR. The study also indicates that CD22 CAR-NK cells could be used in other cancers and more in vivo experiments are needed. © 2023. BioMed Central Ltd., part of Springer Nature.
| Authors | Liu T, Dai X, Xu Y, Guan T, Hong L, Zaib T, Zhou Q, Cheng K, Zhou X, Ma C, Sun P |
|---|---|
| Journal | Journal of translational medicine |
| Publication Date | 2023 Oct 10;21(1):710 |
| PubMed | 37817249 |
| PubMed Central | PMC10563326 |
| DOI | 10.1186/s12967-023-04409-8 |